ReviewJACC. CardioOncology2026
Disease Prognosis and Progression in Transthyretin Amyloidosis: JACC: CardioOncology State-of-the-Art Review.
Review in JACC. CardioOncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Hereditary Transthyretin Cardiac Amyloidosis With Severe Left Ventricular Outflow Tract Obstruction Mimicking Hypertrophic Obstructive Cardiomyopathy.JACC. Case reports · 2026Article
- Agreement between SPECT/CT-derived autoplanar imaging and conventional planar imaging inAnnals of nuclear medicine · 2026Article
- Machine Learning-Driven Risk Prediction Model in Transthyretin Amyloid Cardiomyopathy.JAMA cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transthyretin amyloidosis (ATTR) is a rapidly evolving disease with a rising prevalence and improving prognosis. With an increasing number of patients diagnosed across a broad spectrum of disease stages, disease prognostication is pivotal to guiding therapeutic decisions. Similarly, with varying phenotypes identified and an expanding range of disease-modifying treatments available, the timely identification of cardiac and extracardiac disease progression remains essential. In this review, the authors highlight the current state of knowledge for disease prognosis and progression in ATTR. They focus on clinical, biomarker, functional, and imaging markers of cardiac disease progression. The authors also highlight the need for further investigation into neurologic and other noncardiac indicators of disease progression. Finally, they discuss current approaches and future directions for disease monitoring in ATTR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.